← Back to Search

PET-CT for Liver Cancer

N/A

Waitlist Available

Led By Joshua Meyer, MD

Research Sponsored by Fox Chase Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial looks at how well PET-CT works in finding the right dose of radiation for patients with liver cancer.

Eligible Conditions

Liver Cancer
Cholangiocarcinoma
Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Local control

Radiation dose to 70% of the tumor volume, evaluated using PET-CT

Secondary outcome measures

Ability of PET-CT to reproducibly determine dose to tumor, normal liver, and other surrounding organs

Change in dose measured by PET-CT scan

Distribution of activity measured by PET-CT

+2 more

Side effects data

From 2017 Phase 2 trial • 14 Patients • NCT01437488

64%

Fatigue

43%

Diarrhea

36%

Constipation

36%

Anemia

36%

Nausea

21%

Creatinine Increased

21%

Lightheadedness

21%

Vomiting

21%

Hypokalemia

14%

Abdominal Pain

14%

Back Pain

14%

Dizziness

14%

Fever

14%

Flu-Like symptoms

14%

Hypomagnesia

14%

Pinching sensation around port

14%

Shortness of Breath

14%

URI

14%

Abdominal cramping

14%

Insomnia

14%

Thrombocytopenia

Dry Skin

Decreased Appetite

Bloating

Sacral Edema

Tinnitus

Blood in Bilirubin increased

Tearing

Acid Reflux

INR increased

Embolic stroke

Pulmonary Embolism

Anorexia

Anxiety

Dyspnea

Dysuria

Fall

Flatulence

Foot Pain

Hematoma

Leg pain

Loose Stools

mild-mod Congestion

Neutrophil count decreased

Neuropathy

Rib pain

Throat discomfort

Urinary incontinence

Urinary Tract Obstruction

Worsening pain

Vision changes

Hypoxia

Abdominal distention

Alkalosis

Bladder Spasm

Blurred Vision

Bone Pain

Cabazitaxel Infusion reaction

Change in Taste

Epigastric Pain

Hematuria

Hypophosphatemia

Hypertension

Pain in Pelvis

Paresthesia bilateral feet

Perioral numbness

Peripheral Neuropathy

Weakness

Weight loss

Tachycardia

Bleeding Gums

PTT prolonged

Pyelonephritis

Rash

100%

80%

60%

40%

20%

Study treatment Arm

Cabazitaxel

Trial Design

1Treatment groups

Experimental Treatment

Group I: Diagnostic: PET scan - CT scanExperimental Treatment3 Interventions

Patients undergo PET-CT scan before and after standard radioembolization on day 0. A subset of patients undergo PET-CT scan on day 1, 24 hours after the day 0 post-treatment PET-CT.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CT Scan

2016

Completed Phase 2

~570

PET scan

2016

Completed Phase 2

~650

hepatic artery embolization

2014

Completed Phase 3

~160

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Fox Chase Cancer CenterLead Sponsor

227 Previous Clinical Trials

37,465 Total Patients Enrolled

2 Trials studying Liver Cancer

709 Patients Enrolled for Liver Cancer

Joshua Meyer, MDPrincipal InvestigatorFox Chase Cancer Center

6 Previous Clinical Trials

179 Total Patients Enrolled

Media Library

CT Scan Clinical Trial Eligibility Overview. Trial Name: NCT02088775 — N/A

Liver Cancer Research Study Groups: Diagnostic: PET scan - CT scan

Liver Cancer Clinical Trial 2023: CT Scan Highlights & Side Effects. Trial Name: NCT02088775 — N/A

CT Scan 2023 Treatment Timeline for Medical Study. Trial Name: NCT02088775 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals still being enrolled for the trial?

"Unfortunately, according to the clinicaltrials.gov listing, this medical research is not open for recruitment at present despite being first posted in February 2014 and most recently updated in July 2022. However, there are 1,968 other studies that are actively seeking participants right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer

2014. "PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02088775.